Overview
- The OpenAI Foundation said it is finalizing more than $100 million in grants across six research centers to speed Alzheimer’s research as the first major outlay of its $1 billion 2026 pledge.
- Funding will back four tracks: AI maps of disease pathways, AI-assisted drug design with lab testing, open datasets to predict drug activity and disease course, and new biomarkers to improve diagnosis and clinical trials.
- Early grantees include UCSF and the UW Medicine Institute for Protein Design, which plan to test AI-designed molecules in cells, tissues, and animals before any clinical trials.
- Jacob Trefethen is leading the life sciences program, and the strategy favors repurposing FDA-approved drugs to shorten the path from discovery to patient use.
- The scale marks a sharp jump from $7.6 million in total grants in 2024 and follows OpenAI’s 2025 recapitalization that unlocked a long-term $25 billion pledge.